Form 8-K - Current report:
SEC Accession No. 0001140361-24-040508
Filing Date
2024-09-09
Accepted
2024-09-09 08:00:18
Documents
13
Period of Report
2024-09-04
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20035639x1_8k.htm   iXBRL 8-K 39817
  Complete submission text file 0001140361-24-040508.txt   181337

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bngo-20240904.xsd EX-101.SCH 3886
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bngo-20240904_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bngo-20240904_pre.xml EX-101.PRE 16058
16 EXTRACTED XBRL INSTANCE DOCUMENT ny20035639x1_8k_htm.xml XML 4234
Mailing Address 9540 TOWNE CENTRE DRIVE SUITE 100 SAN DIEGO CA 92121
Business Address 9540 TOWNE CENTRE DRIVE SUITE 100 SAN DIEGO CA 92121 (858) 888-7600
Bionano Genomics, Inc. (Filer) CIK: 0001411690 (see all company filings)

EIN.: 261756290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38613 | Film No.: 241285877
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)